Abstract:ABSTRACT Background: Primary aldosteronism (PA) is the predominant cause of secondary hypertension, leading to cardiovascular and renal damage via mechanisms such as oxidative stress and fibrosis. However, current epidemiology findings on the association between PA and estimated glomerular filtration rate (eGFR) remain inconsistent. Methods: A 1:1 sex- and age-matched case-control study was conducted among participants with PA, essential hypertension (EH), and normotension, with 204 participants in each group. Multiple linear regression was used to explore the correlations of PA, plasma aldosterone concentration (PAC), plasma renin concentration (PRC), and the aldosterone-to-renin ratio (ARR) with eGFR. Additionally, we performed a bidirectional two-sample mendelian randomization (MR) analysis to assess the causal relationship between PA and eGFR based on public genome wide association study (GWAS) databases, and established a multivariable MR (MVMR) analysis to further explore whether the causal effect of PA on eGFR decline independent of systolic (SBP) or diastolic blood pressure (DBP). Results: Multiple linear regression model showed that PA was associated with a decline eGFR (β = -0.234, [95% CI, -0.099, -0.039], P<0.001) after adjusted potential confounders. When stratified the PA patients into three groups according to the levels of PAC, PRC and ARR, patients in the highest PAC groups (β = -0.146 [95% CI, -0.093, -0.008], P =0.021), the lowest PRC group (β = -0.127 [95% CI, -0.084, -0.004], P =0.033), and the highest ARR group (β = -0.147 [95% CI, -0.092, -0.009], P =0.017) had much lower eGFR compared to the EH group. The inverse associations mentioned above remained significant even further adjusted for SBP or DBP, respectively. Besides, MR results indicated that genetically predicted PA was causally associated with a decline eGFR (β =-6.671×10-4[95% CI,-1.291×10-4,-4.328×10-5], P = 0.036), consistent effects were further detected in SBP (β =-1.121×10-3 [95% CI,-2.132×10-3,-1.110×10-4], P = 0.029) or DBP (β =-1.542×10-3,[95% CI,-2.693×10-3,-3.912×10-4], P = 0.008) adjusted model using MVMR analysis. Conclusion: Our study indicates that PA is causally associated with lower eGFR independent of blood pressure, and the adverse effects might be greater than negative controls or EH patients.

Higher risk of chronic kidney disease and progressive kidney function impairment in primary aldosteronism than in essential hypertension. Case-control study

Stroke Risks in Primary Aldosteronism with Different Treatments: A Systematic Review and Meta-Analysis

Cardiovascular Risk in Primary Aldosteronism

Cardiovascular Risk In Primary Aldosteronism A Systematic Review And Meta-Analysis

Electrical and Myocardial Remodeling in Primary Aldosteronism

Comparison of Clinical Features between Primary Aldosteronism and Essential Hypertension in Chinese Patients: A Case-Control Study

Non-Alcoholic Fatty Liver Disease and Hypokalemia in Primary Aldosteronism among Chinese Population.

Impact of primary aldosteronism on kidney function: results from the SPAIN-ALDO registry

Incidence of Metabolic Disorders in Patients with Essential Hypertension and Patients with Primary Aldosteronism

Long-Term Mortality for Patients of Primary Aldosteronism Compared with Essential Hypertension: A Systematic Review and Meta-Analysis

Primary aldosteronism results in a decline estimated glomerular filtration rate independent of blood pressure: evidence from a case-control and mendelian randomization study

Primary Aldosteronism in Chronic Kidney Disease: Blood Pressure Control and Kidney and Cardiovascular Outcomes After Surgical Versus Medical Management

The association between blood pressure variability and renal damage in patients with primary aldosteronism

Renin as a Biomarker to Guide Medical Treatment in Primary Aldosteronism Patients. Findings from the SPAIN-ALDO Registry

Prevalence, Subtype Classification, and Outcomes of Treatment of Primary Aldosteronism: A Prospective Study in China

Assessing the cardiovascular events and clinical Outcomes of COVID-19 on patients with primary aldosteronism: a global analysis of electronic medical records

648 ANALYSIS OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH PRIMARY ALDOSTERONISM

Exploring the Spectrum of Comorbidities Associated with Primary Aldosteronism: Insights from a Large Real-World Case-Control Study

OS 35-06 COMPARISON OF N-TERMINAL PRO-B-TYPE NATRIURETIC PEPTIDE LEVEL IN PRIMARY ALDOSTERONISM AND ESSENTIAL HYPERTENSION

Diurnal blood pressure pattern and cardiac damage in hypertensive patients with primary aldosteronism

Screening and diagnosis of primary aldosteronism. Consensus document of all the Spanish Societies involved in the management of primary aldosteronism